Melanotan II dosage: there is no safe dose, and here’s why

People searching for a melanotan II “dose” are usually looking for a number to copy. The most honest thing this page can do is refuse to hand one over as if it were safe. Melanotan II — MT-2 — has never been approved as a medicine by any regulator, which means there is no licensed dose, no titration label, and no quantity that has been vetted for human use. What circulates instead are microgram protocols passed between users, attached to an unregulated powder of unverified strength. Before any of the numbers below, read the full risk picture in our melanotan II evidence monograph. This page exists to explain the dosing conversation, and to explain why every part of it is built on sand.

There is no approved dose — start there

The foundation of safe dosing for any drug is a regulator-approved label: a tested quantity, a route, a schedule, and a known product. MT-2 has none of these. It was never licensed for tanning, libido, appetite or anything else, so there is no authority that has ever signed off on a dose.^[1] That single fact reframes everything else: the figures people share are not “low doses” or “safe doses,” they are simply the amounts some users happen to inject. Calling any of them a dose in the clinical sense gives them a legitimacy they have not earned.

What users actually do — described, not endorsed

For transparency rather than instruction, the protocol traded online has a recognisable shape. Users typically describe a “loading” phase of small daily subcutaneous injections measured in a few hundred micrograms, followed by a “maintenance” phase of less frequent dosing once the desired skin darkening appears. The reconstitution maths — turning a powder vial into microgram-per-unit figures on an insulin syringe — is the same arithmetic we explain neutrally in our peptide reconstitution calculator. None of this rests on trial data. There is no published dose-finding study establishing that any of these amounts is effective at one level and safe at another; the protocol is folklore, not pharmacology.

The harms are dose-related — which is what makes dosing dangerous

The core problem with chasing a melanotan II dose is that its adverse effects are not random — many of them rise with how much enters the body. The common short-term effects, nausea and facial flushing, cluster around injection and are reported more with larger amounts. More seriously, MT-2 affects the cardiovascular system, with blood-pressure changes documented in the literature, and a published case has linked its use to renal infarction.^[5] Priapism — a prolonged, painful erection that is a urological emergency — has been reported specifically in the context of MT-2 overdose, which is the clearest possible signal that more drug means more harm.^[4] The blood-pressure surges have also been tied to posterior reversible encephalopathy syndrome, a serious neurological event involving headache, visual disturbance and seizures.^[6] When the side-effect curve climbs with the dose and there is no validated dose to begin with, “how much should I take” is the wrong question.

The mole problem turns dosing into a surveillance hazard

Because MT-2 works by driving melanocyte activity, the effect that defines it is also its most worrying dose-linked harm. Clinicians have documented changes in moles after use of an unlicensed “sun tan jab,” raising concern that the drug masks or accelerates the very changes used to detect melanoma early.^[2] One report described new naevi erupting and existing moles darkening within a single day of one injection — a fast, striking melanocytic response.^[3] The implication for dosing is unsettling: the amount that produces a satisfying tan is the same amount altering pigmented lesions in ways that can hide a developing cancer. A peer-reviewed review of the risks of unregulated α-MSH analogue use treats this as a central reason for caution.^[1] For more on the wider melanocortin family, see our melanotan 1 vs melanotan 2 comparison.

Regulators have warned against it, not regulated a dose for it

It would be a mistake to read “no approved dose” as a gap waiting to be filled. Regulators have actively warned the public away from these products. The U.S. Food and Drug Administration has cautioned that melanotan products are unapproved and that injectable tanning agents marketed online are illegal and unsafe. (FDA on tanning products) In the United Kingdom, the Medicines and Healthcare products Regulatory Agency has repeatedly warned that melanotan I and II are unlicensed, that selling them is illegal, and that people have been harmed by them. (UK MHRA warning) The regulatory verdict, in other words, is not a missing label — it is an active red flag.

It is not afamelanotide — the approved drug has a real dose, MT-2 does not

A common way people talk themselves into a melanotan II dose is by pointing to afamelanotide (Scenesse), a melanocortin analog that is approved — but for a specific rare disease, erythropoietic protoporphyria, and given as a controlled-release implant under medical supervision on a defined schedule, with its approval resting on a randomized controlled trial.^[7] That approved product having a real, supervised dose says nothing about MT-2. They are different molecules with opposite regulatory status, and the existence of a licensed cousin does not lend MT-2 a safe dose by association. Treating “it’s basically the approved one” as a dosing justification is one of the most dangerous moves in this marketplace.

The honest bottom line on dosing

If you reduce melanotan II dosing to what the evidence supports, the answer is uncomfortable but clear: there is no established safe dose, the protocols people share are folklore attached to an unverified powder, and the harms — nausea, blood-pressure effects, priapism, renal and neurological events, and the mole changes that undermine melanoma surveillance — rise with the amount injected.^[1][2][4] Regulators warn against the product rather than license a dose for it. The safest dose is none, and any decision about sourcing or use belongs with a clinician who can monitor the real risks, not with a vendor selling milligrams of an unknown. For better-supported options, browse our peptide evidence matrix and the broader sourcing problem in where to get peptides safely.